Announcement

Collapse
No announcement yet.

Mavenclad Effectively Lowers Relapse Rates, Study Comparing DMTs Finds

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Mavenclad Effectively Lowers Relapse Rates, Study Comparing DMTs Finds

    Mavenclad (cladribine) appears to be better at lowering relapse rates during the first two years of disease in relapsing-remitting multiple sclerosis (RRMS) patients than other MS therapies, including interferon, Copaxone (glatiramer acetate) and Tecfidera (dimethyl fumarate), a head-to-head observational study found.

    https://multiplesclerosisnewstoday.c...t-study-finds/
    PPMS for 22 years (dx 1998)
    ~ Worrying will not take away tomorrow's troubles ~ But it will take away today's peace. ~
Working...
X